Impact of different tumour stroma assessment methods regarding podoplanin expression on clinical outcome in patients with invasive ductal breast carcinoma

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1447-1456

  Pula, Bartosz ^a,b   Wojnar, Andrzej ^c   Werynska, Bozena ^b   Ambicka, Aleksandra ^d   Kruczak, Anna ^d   Witkiewicz, Wojciech ^a   Ugorski, Maciej ^e,f   Podhorska Okolow, Marzena ^a,b   Dziegiel, Piotr ^a,b,g  

^a REGIONAL SPECIALIST HOSPITAL   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c 4th Department of Internal Medicine and Pulmonology   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e WROCLAW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^f INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^g UNIVERSITY OF WROC AW   (Poland)

Author keywords

Assessment methods; Breast cancer; Cancer associated fibroblasts; IHC; Podoplanin

Indexed keywords

PODOPLANIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ASSOCIATED FIBROBLAST; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBROBLASTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; STROMAL CELLS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84876774153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K and Kerjaschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154: 385-394, 1999. (Pubitemid 29094089)
2. Farr AG, Berry ML, Kim A, Nelson AJ, Welch MP and Aruffo A: Characterization and cloning of a novel glycoprotein expressed by stromal cells in T-dependent areas of peripheral lymphoid tissues. J Exp Med 176: 1477-1482, 1992.
3. Gandarillas A, Scholl FG, Benito N, Gamallo C and Quintanilla M: Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 20: 10-18, 1997. (Pubitemid 27461534)
4. Zimmer G, Oeffner F, Von Messling V, Tschernig T, Groness HJ, Klenk HD and Herrler G: Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem J 341(Pt 2): 277-284, 1999. (Pubitemid 29373650)
5. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M and Tsuruo T: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 278: 51599-51605, 2003. (Pubitemid 38020404)
6. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G and Detmar M: T1α/Podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22: 3546-3556, 2003. (Pubitemid 36898332)
7. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong Y-K and Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166: 913-921, 2005. (Pubitemid 40315647)
8. Sonne SB, Herlihy AS, Hoei-Hansen CE, Nielsen JE, Almstrup K, Skakkebaek NE, Marks A, Leffers H and Rajpert-De Meyts E: Identity of M2A (D2-40) antigen and GP36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch 449: 200-206, 2006.
9. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J and Quintanilla M: Characterization of human PA2.26 antigen (T1α-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113: 899-910, 2005. (Pubitemid 40096869)
10. Kashima TG, Dongre A, Flanagan AM, Hogendoorn PC, Taylor R and Athanasou NA: Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. Virchows Arch 459: 41-46, 2011.
11. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D and Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272, 2006.
12. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T and Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 111: 483-488, 2006.
13. Kadota K, Huang CL, Liu D, Nakashima N, Yokomise H, Ueno M and Haba R: The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer. Lung Cancer 70: 88-93, 2010.
14. Kreppel M, Scheer M, Drebber U, Ritter L and Zoller JE: Impact of podoplanin expression in oral squamous cell carcinoma: Clinical and histopathologic correlations. Virchows Arch 456: 473-482, 2010.
15. Rahadiani N, Ikeda J, Makino T, Tian T, Qiu Y, Mamat S, Wang Y, Doki Y, Aozasa K and Morii E: Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg Oncol 17: 1311-1323, 2010.
16. Rodrigo JP, Garcia-Carracedo D, Gonzalez M V, Mancebo G, Fresno MF and Garcia-Pedrero J: Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. Mol Cancer 9: 48, 2010.
17. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J, Wojnar A, Witkiewicz W, Rys J, Ugorski M, Dziegiel P and Podhorska-Okolow M: Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 59: 1249-1260, 2011.
18. Ito M, Ishii G, Nagai K, Maeda R, Nakano Y and Ochiai A: Prognostic impact of cancer-associated stromal cells in stage I lung adenocarcinoma patients. Chest 2012.
19. Kitano H, Kageyama S, Hewitt SM, Hayashi R, Doki Y, Ozaki Y, Fujino S, Takikita M, Kubo H and Fukuoka J: Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch Pathol Lab Med 134: 1520-1527, 2010.
20. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K and Ochiai A: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123: 1053-1059, 2008.
21. Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, Watanabe M and Hirohashi S: Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 77: 53-62, 2009.
22. Carvalho FM, Zaganelli FL, Almeida BG, Goes JC, Baracat EC and Carvalho JP: Prognostic value of podoplanin expression in intratumoral stroma and neoplastic cells of uterine cervical carcinomas. Clinics 65: 1279-1283, 2010.
23. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y and Tsuneyoshi M: Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol 21: 256-264, 2008. (Pubitemid 351304278)
24. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, Sasaki H and Ochiai A: Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: Podoplanin in fibroblast functions for tumor progression. Cancer Res 71: 4769-4779, 2011.
25. Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H and Birner P: Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 2012.
26. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
27. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
28. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR and Polyak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32, 2004. (Pubitemid 38903159)
29. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL and Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005. (Pubitemid 40692295)
30. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S and Kuliopulos A: PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313, 2005. (Pubitemid 40222426)
31. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ and Werb Z: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98: 137-146, 1999. (Pubitemid 29344902)
32. Kanner WA, Galgano MT and Atkins KA: Podoplanin expression in basal and myoepithelial cells: Utility and potential pitfalls. Appl Immunohistochem Mol Morphol 18: 226-230, 2010.
33. Sugimoto H, Mundel TM, Kieran MW and Kalluri R: Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640-1646, 2006.
34. Zeisberg EM, Potenta S, Xie L, Zeisberg M and Kalluri R: Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67: 10123-10128, 2007. (Pubitemid 350070783)
35. Allen M and Louise Jones J: Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J Pathol 223: 162-176, 2011.
36. Ito S, Ishii G, Hoshino A, Hashimoto H, Neri S, Kuwata T, Higashi M, Nagai K and Ochiai A: Tumor promoting effect of podoplanin-positive fibroblasts is mediated by enhanced RhoA activity. Biochem Biophys Res Commun 422: 194-199, 2012.
37. Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Giercksky KE and Nesland JM: Breast carcinoma vascularity: A comparison of manual microvessel count and Chalkley count. Histol Histopathol 24: 1049-1059, 2009.
38. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, Doughty JC and Edwards J: Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 106: 383-388, 2012.
39. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
40. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987 (in German).
41. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Tarkowski R, Wlodarska I, Spytkowska B, Gisterek I, Matkowski R and Kornafel J: Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinomas of oral cavity. Histol Histopathol 23: 843-851, 2008.
42. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ and Panel M: Thresholds for therapies: Highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009.
43. Schoppmann SF, Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G and Birner P: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis 2012.
44. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6: 392-401, 2006.